Barnas C, Miller C, Ehrmann H, Schett P, Günther V, Fleischhacker W W
Department of Psychiatry, Innsbruck University Hospital, Austria.
Psychopharmacology (Berl). 1990;100(3):361-5. doi: 10.1007/BF02244607.
A marked tendency to increase the dose of piracetam in the treatment of organic mental disorder can be observed in clinical practice. A placebo controlled study comparing two doses (i.e. 6 g and 24 g per die) was performed to evaluate the benefits of high dose piracetam in the treatment of organic mental disorder of chronic alcohol addicts. 60 inpatients participated in the study. Cognitive impairment was verified by various psychological tests on day 0; patients were also evaluated on days 7, 14, 28 and 42 of the trial. While the patients of all three groups showed a significant amelioration during the treatment period, a modest but significant superiority was indicated for the high piracetam dose. There was no difference between the placebo group and the patients receiving low dose piracetam.
在临床实践中可以观察到，在治疗器质性精神障碍时，有明显增加吡拉西坦剂量的趋势。进行了一项安慰剂对照研究，比较了两个剂量（即每天6克和24克），以评估高剂量吡拉西坦治疗慢性酒精成瘾者器质性精神障碍的疗效。60名住院患者参与了该研究。在第0天通过各种心理测试验证认知障碍；在试验的第7天、14天、28天和42天也对患者进行了评估。虽然所有三组患者在治疗期间均有显著改善，但高剂量吡拉西坦显示出适度但显著的优势。安慰剂组和接受低剂量吡拉西坦的患者之间没有差异。
